Actemra
Phase 3Small molecule
BiogenActemra is one of 59 small molecule programs targeting Melanoma. It is currently in Phase 3.
2
Indications
6
Total Trials
1
Active Trials
58
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
947 competitors in Melanoma
#DrugCompanyPhaseTrials
1Nexavar
BayerPhase 3
Libtayo
RegeneronPhase 3
Methylphenidate Hydrochloride
TakedaPhase 3
ABP 234
AmgenPhase 3
HX008
BBinhui Biopharmaceutical Co., Ltd.
Phase 3
Masitinib
AAB Science
Phase 3
Zelboraf
CConrado Roberto Hoffmann Filho
Preclinical
Actemra
BiogenPhase 3
Intron a
Merck & Co.Preclinical
Opdualag
Bristol-Myers SquibbPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Tocilizumab2 trials
Rheumatoid Arthritis2 trials
Immunogenicity1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Actemra. EMBL-EBI & Wellcome Sanger Institute.
- [4]